Press Releases

Jun 19, 2020

FDA approves new Dupixent® (dupilumab) pre-filled pen designed to support more convenient self-administration

* Single-dose (300 mg) pre-filled pen provides additional administration option to adults and adolescents who are prescribed Dupixent
Jun 15, 2020

Sanofi's emerging oncology pipeline highlighted at the AACR Virtual Annual Meeting II

- Preclinical data show anti-tumor activity in Sanofi's investigational compounds, including an oral selective estrogen receptor degrader (SERD) and an anti-CEACAM5 antibody-drug conjugate
Jun 14, 2020

Sanofi and Sobi donate up to 500 million additional IUs of clotting factor to WFH Humanitarian Aid Program

* Additional donation of factor therapy fulfills 2014 pledge to donate up to an unprecedented 1 billion IUs for humanitarian use
Jun 2, 2020

Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple

Sarclisa added to carfilzomib and dexamethasone (Sarclisa combination) reduced risk of disease progression or death by 47% versus standard of care carfilzomib and dexamethasone (Kd) alone
May 29, 2020

Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time

Across all groups combined, complete responses (CR) are now 16%; in the metastatic group with the longest follow-up, CRs are 20% representing a 200% increase over two years

Show per page

Print
Email page
RSS